PREDICT - PRostate cancer Enhanced Diagnosis by Calibration Technology

Gold Standard Phantoms Limited, a University College London spinout, has conceived a ground-breaking solution to elevate the accuracy of cancer diagnosis through Magnetic Resonance Imaging (MRI). The revolutionary calibration tool, CARE™, has been developed to bolster radiologists' confidence in interpreting MRI measurements, especially in detecting early signs of lesion transformation in prostate cancer patients.

The CARE™ solution lies at the heart of the PREDICT project, a forward-thinking initiative that targets the enhancement of prostate cancer diagnosis. With its unique calibration capability, CARE™ provides a significant advantage over the use of phantoms for calibration of MRI scanners, generally impractical and therefore often underused. Its ease of implementation in everyday patient scans will revolutionise prostate cancer diagnosis through the implementation of true quantitative MRI metrics.

One of the standout benefits of CARE™ is the potential for cross-institutional measurement comparison. This capability opens the path to the creation of new guidelines, including specific thresholds for defining cancerous lesions – an achievement currently thwarted by the lack of MRI scanner calibration. The establishment of such guidelines is of profound interest to radiologists, as it would further solidify their critical role in diagnostics.

In addition, CARE™'s calibration system enables the use of Computer-Aided Detection (CAD)-based Artificial Intelligence (AI) in MRI for the first time, a strategy presently employed in other quantitative imaging methods like X-ray and CT scans. This innovation promises significant productivity and efficiency gains for radiologists.